Robert L. Kampen

2.5k total citations · 1 hit paper
23 papers, 2.0k citations indexed

About

Robert L. Kampen is a scholar working on Immunology, Transplantation and Surgery. According to data from OpenAlex, Robert L. Kampen has authored 23 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 12 papers in Transplantation and 7 papers in Surgery. Recurrent topics in Robert L. Kampen's work include T-cell and B-cell Immunology (13 papers), Renal Transplantation Outcomes and Treatments (11 papers) and Immunotherapy and Immune Responses (7 papers). Robert L. Kampen is often cited by papers focused on T-cell and B-cell Immunology (13 papers), Renal Transplantation Outcomes and Treatments (11 papers) and Immunotherapy and Immune Responses (7 papers). Robert L. Kampen collaborates with scholars based in United States, United Kingdom and Italy. Robert L. Kampen's co-authors include Allan D. Kirk, S. John Swanson, David M. Harlan, Douglas K. Tadaki, Roslyn B. Mannon, David E. Kleiner, Steven C. Hoffmann, Douglas A. Hale, Justin D. Berning and Noelle B. Patterson and has published in prestigious journals such as Nature Medicine, The Journal of Immunology and Brain.

In The Last Decade

Robert L. Kampen

23 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates

1999 666 citations Allan D. Kirk, Linda C. Burkly et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert L. Kampen United States	15	966	930	690	358	225	23	2.0k
María P. Hernández-Fuentes United Kingdom	27	1.2k 1.3×	1.6k 1.7×	647 0.9×	444 1.2×	250 1.1×	69	2.7k
James M. Mathew United States	29	1.0k 1.1×	903 1.0×	754 1.1×	239 0.7×	180 0.8×	108	2.1k
Catharine M. Chase United States	22	726 0.8×	1.1k 1.2×	860 1.2×	158 0.4×	122 0.5×	39	2.0k
Ewa Jankowska−Gan United States	25	548 0.6×	1.3k 1.4×	577 0.8×	351 1.0×	419 1.9×	61	2.4k
Alan Ting United Kingdom	22	593 0.6×	996 1.1×	466 0.7×	205 0.6×	161 0.7×	40	2.1k
Eric T. Elwood United States	16	591 0.6×	1.8k 1.9×	1.1k 1.6×	211 0.6×	222 1.0×	37	3.1k
T. Mohanakumar United States	21	473 0.5×	520 0.6×	692 1.0×	91 0.3×	139 0.6×	74	1.4k
Eric K. Ho United States	24	692 0.7×	605 0.7×	980 1.4×	126 0.4×	76 0.3×	51	1.7k
Annette M. Jackson United States	24	1.2k 1.2×	601 0.6×	772 1.1×	144 0.4×	93 0.4×	85	1.8k
Nicole M. Valenzuela United States	21	859 0.9×	545 0.6×	682 1.0×	133 0.4×	85 0.4×	51	1.3k

Countries citing papers authored by Robert L. Kampen

Since Specialization

Citations

This map shows the geographic impact of Robert L. Kampen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert L. Kampen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert L. Kampen more than expected).

Fields of papers citing papers by Robert L. Kampen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert L. Kampen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert L. Kampen. The network helps show where Robert L. Kampen may publish in the future.

Co-authorship network of co-authors of Robert L. Kampen

This figure shows the co-authorship network connecting the top 25 collaborators of Robert L. Kampen. A scholar is included among the top collaborators of Robert L. Kampen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert L. Kampen. Robert L. Kampen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Singh, Kimberly A., et al.. (2009). Renal epithelial cell-derived monocyte colony stimulating factor as a local informant of renal injury and means of monocyte activation. Transplant International. 22(7). 730–737. 7 indexed citations

Dalakas, Marinos C., Goran Rakočević, Jan Schmidt, et al.. (2009). Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 132(6). 1536–1544. 143 indexed citations

Weaver, Tim, Ali H. Charafeddine, Avinash Kumar Ágarwal, et al.. (2009). Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nature Medicine. 15(7). 746–749. 144 indexed citations

Kirk, Allan D., Tim Weaver, Ali H. Charafeddine, et al.. (2008). TARGETING OF COSTIMULATION BLOCKADE RESISTANT T - EFFECTOR MEMORY (TEM) CELLS IN NON-HUMAN PRIMATE RENAL TRANSPLANTATION WITH LFA-3-IG (ALEFACEPT) PROLONGS ALLOGRAFT SURVIVAL. Transplantation. 86(2S). 107–107. 1 indexed citations

Kirk, Allan D., Roslyn B. Mannon, David E. Kleiner, et al.. (2005). Results from a Human Renal Allograft Tolerance Trial Evaluating T-Cell Depletion with Alemtuzumab Combined with Deoxyspergualin. Transplantation. 80(8). 1051–1059. 91 indexed citations

Hoffmann, Steven C., Douglas A. Hale, David E. Kleiner, et al.. (2005). Functionally Significant Renal Allograft Rejection Is Defined by Transcriptional Criteria. American Journal of Transplantation. 5(3). 573–581. 102 indexed citations

Mannon, Roslyn B., Steven C. Hoffmann, Robert L. Kampen, et al.. (2005). Molecular Evaluation of BK Polyomavirus Nephropathy. American Journal of Transplantation. 5(12). 2883–2893. 94 indexed citations

Light, Jimmy A., et al.. (2004). Human Renal Allograft Rejection Despite the Absence of Allogeneic Passenger Leukocytes. American Journal of Transplantation. 4(2). 283–285. 4 indexed citations

Grimmond, Terry, Carrie Taylor, Richard H. Creech, et al.. (2003). Sharps injury reduction using Sharpsmart™—a reusable sharps management system. Journal of Hospital Infection. 54(3). 232–238. 16 indexed citations

10.

Kirk, Allan D., Douglas A. Hale, Roslyn B. Mannon, et al.. (2003). RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52-SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH-1H). Transplantation. 76(1). 120–129. 340 indexed citations

11.

Hale, Douglas A., S. John Swanson, Roslyn B. Mannon, et al.. (2003). Immunologic monitoring of the transplant recipient: challenges and approaches with antibody induction. Transplantation Reviews. 17(4). S20–S25. 1 indexed citations

12.

Xu, He, Douglas K. Tadaki, Eric A. Elster, et al.. (2002). Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. Transplantation. 74(7). 940–943. 29 indexed citations

13.

Montgomery, Sean P., He Xu, Douglas K. Tadaki, et al.. (2002). Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation. 74(10). 1365–1369. 51 indexed citations

14.

Hoffmann, Steven C., Robert L. Kampen, Shashi Amur, et al.. (2002). Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation. 74(7). 916–923. 81 indexed citations

15.

Kirk, Allan D., Douglas K. Tadaki, Abbie Celniker, et al.. (2001). INDUCTION THERAPY WITH MONOCLONAL ANTIBODIES SPECIFIC FOR CD80 AND CD86 DELAYS THE ONSET OF ACUTE RENAL ALLOGRAFT REJECTION IN NON-HUMAN PRIMATES1. Transplantation. 72(3). 377–384. 108 indexed citations

16.

Xu, He, Eric A. Elster, D. Scott Batty, et al.. (2001). Effects of dose and duration of anti-CD154 antibody therapy in preventing renal allograft rejection in a nonhuman primate model. Transplantation Proceedings. 33(1-2). 223–224. 20 indexed citations

17.

Kirk, Allan D., Douglas K. Tadaki, He Xu, et al.. (2000). PRIMATE ALLOTRANSPLANTATION USING COSTIMULATION BLOCKADE.. Transplantation. 69(Supplement). S414–S414. 3 indexed citations

18.

Chute, John P., et al.. (1999). A comparative study of the cell cycle status and primitive cell adhesion molecule profile of human CD34+ cells cultured in stroma-free versus porcine microvascular endothelial cell cultures. Experimental Hematology. 27(2). 370–379. 30 indexed citations

19.

Kirk, Allan D., Linda C. Burkly, D. Scott Batty, et al.. (1999). Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nature Medicine. 5(6). 686–693. 666 indexed citations breakdown →

20.

Kirk, Allan D., David M. Harlan, Linda C. Burkly, et al.. (1998). Costimulation Blockade in Non-human Primate Renal Allotransplantation. Transplantation. 66(8). S6–S6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact